293 related articles for article (PubMed ID: 1549202)
21. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
[No Abstract] [Full Text] [Related]
22. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
23. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
24. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
Stocchi F; Zappia M; Dall'Armi V; Kulisevsky J; Lamberti P; Obeso JA;
Mov Disord; 2010 Sep; 25(12):1881-7. PubMed ID: 20669296
[TBL] [Abstract][Full Text] [Related]
25. Treating motor fluctuations with controlled-release levodopa preparations.
Koller WC; Pahwa R
Neurology; 1994 Jul; 44(7 Suppl 6):S23-8. PubMed ID: 8047257
[TBL] [Abstract][Full Text] [Related]
26. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
Nyholm D
Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
[TBL] [Abstract][Full Text] [Related]
27. The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Rodnitzky RL
Neurology; 1992 Jan; 42(1 Suppl 1):44-50; discussion 57-60. PubMed ID: 1549201
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
29. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
30. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Goetz CG; Tanner CM; Gilley DW; Klawans HL
Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
[TBL] [Abstract][Full Text] [Related]
31. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
32. Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
Koller WC
Neurology; 1992 Jan; 42(1 Suppl 1):4-5; discussion 57-60. PubMed ID: 1549200
[No Abstract] [Full Text] [Related]
33. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.
Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA
Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966
[TBL] [Abstract][Full Text] [Related]
34. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
[TBL] [Abstract][Full Text] [Related]
35. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
36. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
[TBL] [Abstract][Full Text] [Related]
37. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
Koller WC; Hutton JT; Tolosa E; Capilldeo R
Neurology; 1999 Sep; 53(5):1012-9. PubMed ID: 10496260
[TBL] [Abstract][Full Text] [Related]
38. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
[TBL] [Abstract][Full Text] [Related]
39. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
Sage JI; Mark MH
Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of sustained dopaminergic stimulation.
Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
